HOME Top Market Reports North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

By: marketsandmarkets.com
Publishing Date: April 2013
Report Code: PH 1868

Discount on Reports  

Enquiry Before Buying
 
purchase report
download pdf  request for customisation


The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

  • Diagnostic
    • SPECT
      • Tc-99m
      • Tl-201
      • Ga-67
      • I-123
      • Others
    • PET
      • F-18
      • Rb-82
      • Others
  • Therapy
    • Beta emitters
      • I-131
      • Sm-153
      • Re-186
      • Y-90
      • Lu-177
      • Others
    • Alpha emitters
    • Brachytherapy
      • Cs-131
      • I-125
      • Pd-103
      • Ir-192
      • Others

North American Enriched Stable Isotopes Market

  • Deuterium
  • Oxygen-18
  • Carbon-13
  • Nitrogen-15
  • Others

North American Radiopharmaceutical and Stable Isotope Markets, By Country

  • U.S.
  • Canada

Customer Interested in this report also can view

Table Of Contents 
 
1 Introduction (Page No.- 26)
  1.1 Key Take-Aways
  1.2 Report Description
  1.3 Markets Covered
  1.4 Stakeholders
  1.5 Research Methodology
      1.5.1 Market Size
      1.5.2 Market Share
      1.5.3 Key Data Points From Secondary Sources
      1.5.4 Key Data Points From Primary Sources
      1.5.5 Assumptions

2 Executive Summary (Page No.- 33)

3 Market Overview (Page No.- 37)
  3.1 Definition Of Radiopharmaceuticals
  3.2 Evolution
  3.3 Market Segmentation
      3.3.1 Radiopharmaceuticals
      3.3.2 Stable Isotopes
  3.4 Market Dynamics
      3.4.1 Drivers
            3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
            3.4.1.2 Increasing Use Of Spect And Pet Scans Results In The Rise Of Radiopharmaceutical Usage
            3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
            3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
      3.4.2 Restraints
            3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals To Restrict Usage
            3.4.2.2 High Capital Demand To Limit The Buying Of Scanners
            3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
            3.4.2.4 Competition From Conventional Diagnostic Procedures
      3.4.3 Opportunities
            3.4.3.1 Ample Number Of Potential Radioisotopes In The Pipeline
            3.4.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
            3.4.3.3 Alternative Diagnostic Radiopharmaceuticals Solution
            3.4.3.4 Cyclotron-Based Production
            3.4.3.5 Neurological Application
      3.4.4 Threat
            3.4.4.1 Shutdown Of Nuclear Reactors Impacts The Production Of Radioisotopes
  3.5 Winning Imperatives
      3.5.1 Investment To Encourage New Radioisotopes And Novel Applications
      3.5.2 Shift Towards Leu Based Mo-99 Production
  3.6 Burning Issues
      3.6.1 High Cost Of Pet Cameras
      3.6.2 Shortage In Supply Of Technetium-99m
  3.7 Supply And Demand Analysis Of Technetium-99m
  3.8 Regulatory Affairs
      3.8.1 U.S.
            3.8.1.1 Fda Approval Process
            3.8.1.2 Transportation
            3.8.1.3 Reimbursement Scenario
      3.8.2 Canada
            3.8.2.1 Nuclear Safety And Control Act
            3.8.2.2 Transportation
            3.8.2.3 Licensing
  3.9 Market Share Analysis
      3.9.1 Radiopharmaceuticals Market
      3.9.2 Enriched Stable Isotopes Market

4 North American Radiopharmaceuticals Market, By Isotope  (Page No.- 61)
  4.1 Introduction
  4.2 Diagnostic Isotopes
      4.2.1 Opportunity Matrix
      4.2.2 Single-Photon Emission Computed Tomography (Spect) Radiopharmaceuticals
            4.2.2.1 Technetium-99m (TC-99M)
                    4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
                    4.2.2.1.2 Factors Affecting Technetium-99m Market
                              4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
                              4.2.2.1.2.2 Lack Of Availability Of Technetium
            4.2.2.2 Thallium-201 (TL-201)
                    4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
            4.2.2.3 Gallium-67 (GA-67)
                    4.2.2.3.1 Fluorine-18 Might Seize GA-67 Market Share In The Near Future
            4.2.2.4 Iodine (I-123)
            4.2.2.5 Others
      4.2.3 Positron Emission Tomography (PET) Radiopharmaceuticals
            4.2.3.1 Fluorine-18
                    4.2.3.1.1 FDG
                    4.2.3.1.2 Florbetapir
                    4.2.3.1.3 Factors Affecting Fluorine-18 Market
                              4.2.3.1.3.1 Increasing Availability Of Pet Machines
                              4.2.3.1.3.2 Rise In Pet Procedures Increases Demand For FDG
                              4.2.3.1.3.3 High Generation Costs Of FDG
                              4.2.3.1.3.4 Need For Speedy & Efficient Transportation
            4.2.3.2 Rubidium-82 (RB-82)
                    4.2.3.2.1 Bracco Re-Launched Cardiogen-82 In FEB-12 
            4.2.3.3 Others
                    4.2.3.3.1 GA-68 Deemed As A Potential Pet Radioisotope
  4.3 Therapeutic Isotopes
      4.3.1 Opportunity Matrix
      4.3.2 Beta Emitters
            4.3.2.1 Iodine-131 (I-131)
            4.3.2.2 Yttrium-90 (Y-90)
                    4.3.2.2.1 Y-90 Market Influenced By Popularity Of Nordion’s Therasphere
            4.3.2.3 Samarium-153 (SM-153)
            4.3.2.4 Rhenium-186 (RE-186)
            4.3.2.5 Lutetium-177 (LU-177)
                    4.3.2.5.1 Lu-177 Is A Potential Treatment Option For Neuroendocrine Cancer
            4.3.2.6 Others
                    4.3.2.6.1 Re-188 And P-33 Are Notable Promising Isotope
      4.3.3 Alpha Emitters
            4.3.3.1 Radium-223 (RA-223) & Alpharadin
                    4.3.3.1.1 Successful Completion Of Phase Iii Trials In Men With Bone Metastases From Crpc
                    4.3.3.1.2 First In-Class Alpha Pharmaceutical
                    4.3.3.1.3 Alpharadin Is Advantageous Over Taxotere, Beta-Therapy And Brachytherapy
                    4.3.3.1.4 Success Of Alpharadin
                    4.3.3.1.5 Porter’s Five Forces Analysis
                    4.3.3.1.6 Swot Analysis
            4.3.3.2 Actinium-225 (AC-225)
            4.3.3.3 Lead-212 (PB-212)/Bismuth-212 (BI-212)
            4.3.3.4 Astatine-211 (AT-211)
            4.3.3.5 Radium-224 (RA-224)
            4.3.3.6 Thorium-227 (TH-227)
      4.3.4 Brachytherapy
            4.3.4.1 U.S. To Show Slow Growth Due To Reimbursement Issues
            4.3.4.2 Cesium-131
            4.3.4.3 Iodine-125
            4.3.4.4 Palladium-103
            4.3.4.5 Iridium-192
            4.3.4.6 Others

5 North American Radiopharmaceuticals Market, By Application/Indications  (Page No.- 113)
  5.1 Introduction
  5.2 Diagnostic Application
      5.2.1 Spect
            5.2.1.1 Cardiology
            5.2.1.2 Lymphoma
            5.2.1.3 Thyroid
            5.2.1.4 Neurology
                    5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drive Growth Of The Neurology Spect Market
            5.2.1.5 Others
      5.2.2 Pet
            5.2.2.1 Oncology
                    5.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
            5.2.2.2 Cardiology
            5.2.2.3 Neurology
                    5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of FDG F-18
            5.2.2.4 Others
  5.3 Therapeutic Application
      5.3.1 Thyroid
      5.3.2 Bone Metastasis
      5.3.3 Lymphoma
            5.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy Market
      5.3.4 Endocrine Tumors
      5.3.5 Others

6 North American Enriched Stable Isotopes Market (Page No.- 136)
  6.1 Introduction
  6.2 Market Overview
  6.3 Market Dynamics
      6.3.1 Drivers
            6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
            6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
            6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
      6.3.2 Restraints
            6.3.2.1 Harmful Effects Of High Doses Of Stable Isotopes Affect Market Growth
            6.3.2.2 High Cost Of Stables Isotope
  6.4 Enriched Stables Market, By Isotope
      6.4.1 Deuterium & O-18 Are Promising Isotopes
      6.4.2 Carbon-13
      6.4.3 Deuterium
      6.4.4 Oxygen-18
      6.4.5 Nitrogen-15
      6.4.6 Other Stable Isotopes
  6.5 Enriched Stables Market, By Application
      6.5.1 Diagnostic & Therapeutic
      6.5.2 Research
      6.5.3 Pharmaceutical
      6.5.4 Industrial Sector

7 Geographic Analysis (Page No.- 154)
  7.1 Introduction
  7.2 U.S.
      7.2.1 Diagnostic Radiopharmaceuticals Market
      7.2.2 Therapeutic Radiopharmaceuticals Market
      7.2.3 Stable Isotope Market
  7.3 Canada
      7.3.1 Diagnostic Radiopharmaceuticals Market
      7.3.2 Therapeutic Radiopharmaceuticals Market
      7.3.3 Stable Isotope Market

8 Competitive Landscape (Page No.- 183)
  8.1 Introduction
  8.2 Mergers & Acquisitions
  8.3 Agreements, Partnerships, Collaborations & Joint Ventures 185
  8.4 Products Launch
  8.5 Expansions
  8.6 Other Developments
  8.7 Approvals

9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*  (Page No.- 195)
  9.1 Bracco Imaging S.P.A.
  9.2 Cambridge Isotope Laboratories, Inc.
  9.3 Cardinal Health, Inc.
  9.4 Covidien, Plc
  9.5 Eczacibasi-Monrol
  9.6 Fujifilm Holdings Corporation
  9.7 Ge Healthcare (Subsidiary Of General Electric Company)
  9.8 Iba Group
  9.9 Isotec, Inc. (Sigma-Aldrich)
  9.10 Lantheus Medical Imaging, Inc.
  9.11 Nordion, Inc.
  9.12 Ntp Radioisotopes (Pty), Ltd.
  9.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
  9.14 Taiyo Nippon Sanso Corporation
  9.15 Triad Isotopes, Inc.
  9.16 Urenco Limited
  9.17 Rotem Industries, Ltd., Inc.
  9.18 Australian Nuclear Association And Technology Organization (ANSTO)
  9.19 Board Of Radiation And Isotope Technology (BRIT)
  9.20 Institute Of Atomic Energy Polatom Radioisotope Centre
  9.21 Institute Of Isotopes Co., Ltd.
  9.22 Institute Of Radioelement (IRE)

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies. 


List Of Tables  (120 Tables)
  
Table 1 North America: Diagnostic Radiopharmaceuticals Market,By Technology, 2010 – 2017 ($Million) 
Table 2 North America: Radioipharmaceuticals Market, By Country, 2010 – 2017 ($Million)
Table 3 North America: Diagnostic Radiopharmaceuticals Market,By Technology, 2010 – 2017 ($Million) 
Table 4 North America: Spect Radiopharmaceuticals Market,By Isotope, 2010 – 2017 ($Million) 
Table 5 North America: Spect Radiopharmaceuticals Market,By Country, 2010 – 2017 ($Million) 
Table 6 Indications Diagnosed By Tc-99m
Table 7 North America: TC-99M Market, By Country, 2010- 2017 ($Million) 
Table 8 North America: Tl-201 Market, By Country, 2010 – 2017 ($Million) 
Table 9 North America: GA-67 Market, By Country, 2010 – 2017 ($Million) 
Table 10 North America: I-123 Market, By Country, 2010 – 2017 ($Million) 
Table 11 North America: Other Radiopharmaceuticals Market,By Country, 2010 – 2017 ($Million) 
Table 12 North America: Pet Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million) 
Table 13 North America: Pet Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 14 North America: F-18 Market, By Country, 2010 – 2017 ($Million) 
Table 15 North America: RB-82 Market, By Country, 2010 – 2017 ($Million) 
Table 16 North America: Other Pet Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million) 
Table 17 North America: Therapeutic Radiopharmaceuticals Market, By Technology 2010 – 2017 ($Million) 
Table 18 North America: Beta Emitters Market, By Isotope, 2010 – 2017 ($Million) 
Table 19 North America: Beta Emitter Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million)
Table 20 North America: I-131 Market, By Country, 2010 – 2017 ($Million) 
Table 21 North America: Y-90 Market, By Country, 2010 – 2017 ($Million) 
Table 22 North America: SM-153 Market, By Country, 2010 – 2017 ($Million) 
Table 23 North America: RE-186 Market, By Country, 2010 – 2017 ($Million) 
Table 24 North America: LU-177 Market, By Country, 2010 – 2017 ($Million) 
Table 25 North America: Other Beta Emitters Market, By Country, 2010 – 2017 ($Million) 
Table 26 Alpha Emitters Vs Beta Emitters
Table 27 Radioisotope Characteristics & Dose Delivery Over Time
Table 28 North America: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million) 
Table 29 North America: Brachytherapy Market, By Country, 2010 – 2017 ($Million) 
Table 30 North America: CS-131 Market, By Country, 2010 – 2017 ($Million) 
Table 31 North America: I-125 Market, By Country, 2010 – 2017 ($Million) 
Table 32 North America: PD-103 Market, By Country, 2010 – 2017 ($Million) 
Table 33 North America: IR-192 Market, By Country, 2010 – 2017 ($Million) 
Table 34 North America: Other Brachytherapy Market, By Country, 2010 – 2017 ($Million)
Table 35 North America: Spect Application Market, 2010 – 2017 ($Million) 
Table 36 North America: Cardiology Spect Market, By Country, 2010 – 2017 ($Million) 
Table 37 North America: Lymphoma Spect Market, By Country, 2010 – 2017 ($Million) 
Table 38 North America: Thyroid Spect Market, By Country, 2010 – 2017 ($Million) 
Table 39 North America: Neurology Spect Market, By Country, 2010 – 2017 ($Million) 
Table 40 North America: Other Spect Applications Market, By Country, 2010 – 2017 ($Million)
Table 41 North America: Pet Market, By Application, 2010 – 2017 ($Million) 
Table 42 North America: Oncology Pet Market, By Country, 2010 – 2017 ($Million) 
Table 43 North America: Cardiology Pet Market, By Country, 2010 – 2017 ($Million) 
Table 44 North America: Neurology Pet Market, By Country, 2010 – 2017 ($Million) 
Table 45 North America: Other Pet Applications Market, By Country, 2010 – 2017 ($Million)
Table 46 North America: Therapeutic Application Market, 2010 – 2017 ($Million) 
Table 47 North America: Radiopharmaceuticals Therapeutic Application Market, By Country, 2010 – 2017 ($Million) 
Table 48 North America: Radiopharmaceuticals Thyroid Application Market, By Country, 2010 – 2017 ($Million)
Table 49 North America: Radiopharmaceuticals Bone Metastasis Application Market, By Country, 2010 – 2017 ($Million)
Table 50 North America: Radiopharmaceuticals Lymphoma Application Market, By Country, 2010 – 2017 ($Million)
Table 51 North America: Radiopharmaceuticals Endocrine Application Market, By Country, 2010 – 2017 ($Million)
Table 52 North America: Radiopharmaceuticals Other Application Market, By Country, 2010 – 2017 ($Million)
Table 53 North America: Stable Isotope Market, 2010 – 2017 ($Million)
Table 54 North America: Stable Isotope Market, By Country, 2010 – 2017 ($Million) 
Table 55 North America: Carbon Stable Isotope Market, By Country, 2010 – 2017 ($Million)
Table 56 North America: Deuterium Stable Isotope Market, By Country, 2010 – 2017 ($Million) 
Table 57 North America: Oxygen Stable Isotope Market, By Country, 2010 – 2017 ($Million)
Table 58 North America: Nitrogen Stable Isotope Market, By Country, 2010 – 2017 ($Million)
Table 59 North America: Other Stable Isotope Market, By Country, 2010 – 2017 ($Million)
Table 60 North America: Enriched Stable Isotope Market, For Application, 2010 – 2017 ($Million) 
Table 61 North America: Stable Isotopes Market For Diagnostic & Therapy Applications, By Country, 2010 – 2017 ($Million)
Table 62 North America: Stable Isotopes Market For Research Applications, By Country, 2010 – 2017 ($Million)
Table 63 North America: Stable Isotopes Market For Pharmaceutical Applications, By Country, 2010 – 2017 ($Million)
Table 64 North America: Stable Isotopes Market For Industrial Applications, By Country, 2010 – 2017 ($Million)
Table 65 North America: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 – 2017 ($Million) 
Table 66 North America: Spect Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million) 
Table 67 North America: Spect Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 68 North America: Pet Radiopharmaceuticals Market, By Country, 2010 – 2017 ($Million) 
Table 69 North America: Pet Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 70 North America: Therapeutic Radiopharmaceuticals Market, 2010 – 2017 ($Million)
Table 71 North America: Beta Emitters Market, By Country, 2010 – 2017 ($Million) 
Table 72 North America: Beta Emitters Market, By Isotope, 2010 – 2017 ($Million) 
Table 73 North America: Brachytherapy Market, By Country, 2010 – 2017 ($Million) 
Table 74 North America: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million) 
Table 75 North America: Stable Isotopes Market, By Country, 2010 – 2017 ($Million) 
Table 76 North America: Stable Isotopes Market, 2010 – 2017 ($Million)
Table 77 North America: Stable Isotopes Market, By Application, 2010 – 2017 ($Million) 
Table 78 U.S.: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 – 2017 ($Million) 
Table 79 U.S.: Spect Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 80 U.S.: Pet Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 81 U.S.: Therapeutic Radiopharmaceuticals Market, 2010 – 2017 ($Million) 
Table 82 U.S.: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million)
Table 83 U.S.: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million)
Table 84 U.S.: Stable Isotopes Market, 2010 – 2017 ($Million)
Table 85 Canada: Diagnostic Radiopharmaceuticals Market, By Technology, 2010 – 2017 ($Million) 
Table 86 Canada: Spect Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 87 Canada: Pet Radiopharmaceuticals Market, By Isotope, 2010 – 2017 ($Million) 
Table 88 Canada: Therapeutic Radiopharmaceuticals Market, 2010 – 2017 ($Million) 
Table 89 Canada: Brachytherapy Market, By Isotope, 2010 – 2017 ($Million) 
Table 90 Canada: Beta Emitter Market, By Isotope, 2010 – 2017 ($Million) 
Table 91 Canada: Stable Isotopes Market, 2010 – 2017 ($Million)
Table 92 Mergers & Acquisitions, 2010 – 2012
Table 93 Agreements, Partnerships, Collaborations & Joint Ventures, 2010 – 2013
Table 94 Products Launch, 2010 – 2013
Table 95 Expansion, 2010 – 2012
Table 96 Other Developments, 2010 – 2012
Table 97 Approvals, 2010 – 2012
Table 98 Cambridge Isotope Laboratories Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Table 99 Cambridge Isotope Laboratories Inc.: Total Revenue, By Geography, 2010 – 2012 ($Million) 
Table 100 Cardinal Health, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Table 101 Cardinal Health, Inc.: Total Revenue, By Geography, 2010 – 2012 ($Million) 
Table 102 Covidien, Plc: Total Revenue And R&D Expenditure, 2010 – 2012 ($Million) 
Table 103 Covidien, Plc: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Table 104 Covidien, Plc: Total Revenue, By Geography, 2010 – 2012 ($Million) 
Table 105 Fujifilm Holdings Corp: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Table 106 Fujifilm Holdings Corp: Total Revenue, By Geography, 2010 – 2012 ($Million) 
Table 107 General Electric Company: Total Revenue, By Segment, 2009 – 2011 ($Billion) 
Table 108 General Electric Company: Total Revenue, By Geography, 2009 – 2011 ($Billion) 
Table 109 IBA Group: Market Revenue, By Segment, 2009 – 2011 ($Million) 
Table 110 IBA Group: Total Revenue, By Geography, 2009 – 2011 ($Million) 
Table 111 Isotec Inc.: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 112 Isotec Inc.: Total Revenue, By Geography, 2009 – 2011 ($Million) 
Table 113 Lantheus: Total Revenue, By Segment, 2009 – 2011 ($Million)
Table 114 Lantheus: Total Revenue, By Geography, 2009 – 2011 ($Million) 
Table 115 Nordion, Inc.: Total Revenue, By Segment, 2010 – 2012 ($Million) 
Table 116 Nordion, Inc.: Total Revenue, By Geography, 2010 – 2017
Table 117 Siemens AG: Total Revenue And R&D Expenses, 2010 – 2012 ($Million) 
Table 118 Siemens AG: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 119 Siemens AG: Total Revenue, By Geography, 2010 – 2012 ($Million) 
Table 120 Taiyo Nippon Sanso, Corp.: Total Revenue, By Geography, 2010 – 2012 ($Million) 
 

List Of Figures  (29 Figures)
 
Figure 1 North American Radiopharmaceuticals Market, By Segment, 2010 – 2017
Figure 2 North America Stable Isotopes Market, $Million (2012 – 2017)
Figure 3 Evolution Of Radiopharmaceuticals
Figure 4 Radiopharmaceuticals Market Segmentation
Figure 5 Enriched Stable Isotopes Market Segmentation
Figure 6 Market Dynamics
Figure 7 Supply Chain Of Mo-99/TC-99M Between U.S. And Canada
Figure 8 North America: Radiopharmaceuticals Market Share Analysis, By Key Players, 2012
Figure 9 North America Enriched Stable Isotope Market: Market Share Analysis, By Key Players, 2012
Figure 10 Opportunity Matrix: North American Diagnostic Radiopharmaceuticals Market (2012)
Figure 11 Spect Radiopharmaceuticals Market Share (2012)
Figure 12 Pet Radiopharmaceuticals Market Share (2012)
Figure 13 Opportunity Matrix: North American Therapeutic Radiopharmaceuticals Market (2012)
Figure 14 RA-223 Decay Chain
Figure 15 Porter’s Five Forces Analysis For Alpharadin
Figure 16 Swot Analysis Of Alpharadin
Figure 17 North America: Diagnostic Radiopharmaceuticals Market, By Technology & Indication (2012 – 2017) 
Figure 18 Key Growth Strategies, 2010 – 2013
Figure 19 Cambridge Isotope Laboratories Inc.: Total Revenue And R&D Expenses, 2010 – 2012 ($Billion)
Figure 20 Cardinal Health, Inc.: Total Revenue, 2010 – 2012 ($Billion)
Figure 21 Covidien, Plc: Radiopharmaceuticals Revenue, 2010 – 2012 ($Billion) 
Figure 22 Fujifilm Holdings Corp: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 23 General Electric Company: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion)
Figure 24 IBA Group: Total Market Revenue, 2009 – 2011 ($Million)
Figure 25 Isotec Inc.: Total Revenue And R&D Expenses, 2009 – 2011 ($Billion) 
Figure 26 Lantheus: Total Revenue And R&D Expenses, L2009 – 2011 ($Million) 
Figure 27 Nordion, Inc.: Total Market Revenue, 2010 – 2012 ($Billion)
Figure 28 Taiyo Nippon Sanso, Corp.: Total Revenue And R&D Expenditure, 2010 – 2012 ($Billion)
Figure 29 Urenco Limited: Total Market Revenue, 2009 – 2011, ($Billion)

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used for disease diagnosis and treatment. They provide better understanding of the diseases as they not only give anatomical but also functional information about the organ. Radiopharmaceuticals are also used in the nuclear imaging field as tracers. They are mostly used for diagnosis with the use of gamma cameras for imaging techniques such as in SPECT and PET. Radioisotopes are majorly used in medical applications with more than 90% share. The medical application is being driven by the increasing patient population and new and effective radioisotopes.The most commonly used isotopes for diagnosis are Tc-99m and Tl-201 for SPECT and F-18 for PET.

The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 84% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67) and iodine-123 (I-123). SPECT is majorly used in the diagnosis of cardiac diseases; it is poised to grow at a stable CAGR from 2012 to 2017. The PET radioisotopes market is dominated by fluorine-18 (F-18), followed by rubidium-82 (Rb-82) and poised to grow at a CAGR of more than 12% in the near future.

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131 (I-153), which is poised to grow at a decent CAGR of about 4.0% from 2012 to 2017. The market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkins lymphoma. Significant isotopes in the brachytherapy market are cesium-131 (Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192). The U.S. is the major market for brachytherapy in terms of market share. However, it is showing slow growth due to reimbursement issues.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects,radioisotopes are being preferred by medical practitioners due to minimum or no side effects.The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than half of the share. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc (U.S.).

The stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). It has major applications in research, pharmaceuticals, diagnostic and therapy, and the industrial sector. The diagnostic and therapy market accounted for the maximum share (49%) of the stable isotopes market. The North American stable isotopes market is estimated to reach $85 million by 2017 at a CAGR of 13.0%.

Radiopharmaceuticals Market Share Analysis, By Key Player (2012)

North American Nuclear Medicine Market

Source: Annual Reports, SEC Filings, OECD Publications, NIH, WNA, IAEA, NRC, SNMMI, Nuclear Medicine Associations, Experts Interviews, MnM Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports